Restoring Nerve Function

Solaxa is a clinical-ready biopharmaceutical company developing treatments for
rare neurodegenerative disease and acute nerve injuries.


We are pursuing both novel and reformulated drugs to
restore nerve function by targeting ion channels.

Our Company: By The Numbers

2

Investigator-initiated IND trials funded & enrolling

15

6 issued and 9 pending US, EU, Canada patents exclusively licensed

115

Cerebellar ataxia patients studied with drug

$8M+

Non-dilutive NIH & DoD grants to co-founders

20+

Peer-reviewed publications by co-founders

World-Class Leadership

We’ve assembled an experienced management team and advisors with expertise from small and large biopharma to generate an innovative pipeline addressing the unmet needs in neurology.  

We are passionate scientists, clinicians and commercial experts dedicated to develop therapies for patients globally suffering from nerve diseases and injuries.

Pipeline

Solaxa is developing both novel and reformulated drugs to restore nerve function by targeting ion channels.
Aminopyridines are a potent class of ion channel blockers where Solaxa’s newly discovered and patented mechanisms of action offer treatment advancements in both chronic and acute use.
TARGETINDICATIONPROGRAMPRECLINICALPHASE IPHASE IIPHASE IIIAPPROVAL
Cerebellar AtaxiasLate-OnsetSLX-1002026
PediatricSLX-2002027
Acute Nerve InjuryTrauma and SurgeryConfidential2029
Chemotherapy NeuropathiesConfidential2030

For SLX-100 and SLX-200, we will be referencing safety and dosing from previously published studies not conducted by Solaxa in our 505b2 expedited regulatory submission

Scroll to Top